A lot of Moderna’s Spikevax® vaccine is being recalled due to particulates, just six months after previous contamination concerns were supposedly solved.
List view / Grid view
Evonetix has been granted a European patent for its silicon chips that leverage semiconductor technology to thermally control DNA synthesis.
Research suggests companies are often disappointed by new technologies because they have inflated expectations that do not match the tech's practical capabilities.
The closing of two biologics acquisitions will help Recipharm establish itself in the advanced therapy medicinal products space.
Pzifer's acquisition of ReViral will include its portfolio of promising therapeutic candidates, such as sisunatovir, an orally administered inhibitor designed to block fusion of the RSV virus to the host cell.
New Ultomiris (ravulizumab-cwvz) follow-up data shows sustained functional improvements in certain adults with generalised myasthenia gravis (gMG).
Researchers used computational fluid dynamics (CFD) simulations to assess their cleanroom airflow and suggest improvements that would reduce contamination levels.
The new global paediatric drug development centre of excellence will focus on the creation of paediatric formulations to treat some of the world's most challenging viral diseases.
Novartis’ Vijoice® (alpelisib) is the first and only treatment approved for the treatment of the rare spectrum of conditions associated with PROS in certain patients.
Catalent announces the expansion of its biologics development and manufacturing capability by purchasing a new facility, currently under construction in Oxford, UK.
A team of scientists has developed a spherical nucleic acid (SNA) vaccine, which has demonstrated high efficacy as a COVID-19 therapy, as well as an anti-cancer treatment in rodents.
Four Big Pharma companies have shared previously unpublished hazard data for drug substances to enhance database-dependent computational tools and help reduce animal testing.
FUJIFILM Diosynth Biotechnologies will run the cell therapy manufacturing facility, acquired for $100mn from Atara Biotherapeutics, as part of its global network.
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Lentiviral gene therapy reduces infections and bleeding episodes in children with a severe immune disorder Wiskott–Aldrich syndrome (WAS), finds new study.